Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIO752 in Progressive Supranuclear Palsy
NCT04539041Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2021
- Primary completion
- Oct 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of NIO752 in progressive supranuclear palsy (PSP) (6 arms), sponsored by Novartis. Primary endpoints: Adverse Events at 1 year, Serious Adverse Events at 1 year and 2 more. Started Feb 2021; status: completed.
02
Drugs
NIO752
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT04539041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539041.